
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Atlanta -- The so-called mystery rash is getting more mysterious. In fact, the Centers for Disease Control and Prevention says the hubbub played up in local and national media might be unfounded.